Meisam Naeimi Kararoudi, DVM, PhD

Dr. Naeimi Kararoudi is developing novel gene edited immune cells such as NK cells and T-cells for cancer immunotherapy. As director of the CRISPR/Gene editing core he helps investigators with their CRISPR gene editing in a verity of cells and applications.

Publications

Meisam Naeimi Kararoudi, DVM, PhD, is a research assistant professor of pediatrics at The Ohio State University College of Medicine. He is also the director of CRISPR/Gene editing Core and a principal investigator in the Center for Childhood Cancer at Nationwide Children’s Hospital. He received his veterinary surgery degree from Iran. He obtained his PhD from the University of Perugia, Italy and was trained as an Erasmus scholar at the University of Oxford, UK. Being a veterinary surgeon, immunologist and genetic engineer brought him to Sweden where he used CRISPR/Cas9 to decrease rejection after transplantation of tissue engineered organs at Sahlgrenska University Hospital. During this period, he also worked in SciLifeLab as a visiting Post-Doc to use genetic modification in cancer-related projects. During his postdoc at Dr. Dean Lee’s laboratory, he developed a method to genetically modify the hard-to-transfect human Natural Killer cells using CRISPR, and identified novel approaches to enhance their cytotoxicity and to target cancers via chimeric antigen receptors.